share_log

Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13

Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13

巴克莱维持对Replimune集团的增持,将目标股价下调至13美元
Benzinga ·  2023/12/06 06:36

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $50 to $13.

巴克莱分析师彼得·劳森维持Replimune集团(纳斯达克股票代码:REPL)增持 “增持”,并将目标股价从50美元下调至13美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发